Prognostic role of CD44 cell adhesion molecule expression in primary and metastatic renal cell carcinoma: a clinicopathologic study of 125 cases
Prognostic role of CD44 cell adhesion molecule expression in primary and metastatic renal cell carcinoma: a clinicopathologic study of 125 cases
复制标题
DOI：
10.1007/s00428-007-0530-4
复制
发表时间：
2008-01-01
期刊：
影响因子：
3.5
通讯作者：
Amin, Mahul B.
中科院分区：
文献类型：
--
作者：
Lim, So Dug;Young, Andrew N.;Amin, Mahul B.
CD 44在肾细胞癌（RCC）中可能的预后效用促使其在原发性和转移性RCC中的表达进行比较。用CD 44（标准型）抗体对125例患者的164例原发性RCC和转移性RCC石蜡包埋组织进行免疫染色。它包括随访期间的86例原发性RCC（50例后续转移[MET+]和36例无已知转移[MET-]）和78例转移性RCC（39例仅转移性RCC和39例来自RCC MET +类别的匹配RCC原发性）。CD 44的免疫反应性半定量评分为0、1或2（0，< 5%; 1，5-50%; 2，>= 50%）。与原发性RCC相比，转移性RCC中CD 44的表达显著更高（p=0.036）。原发性RCC（MET-和MET+）中的CD 44免疫反应性与无进展生存期相关（p=0.027）。在转移性RCC中，CD 44免疫反应性也与检测到首次转移后的生存率相关（p=0.011）。在多变量分析中，原发性RCC的分期（p=0.0001）和CD 44免疫反应性（p=0.03）是无进展生存期的独立预测因素。我们的研究表明，RCC中的CD 44状态提供了有用的预后信息，在原发性和转移性RCC，并可能有分层的患者治疗决策的适用性。
Possible prognostic utility of CD44 in renal cell carcinoma (RCC) prompted a comparison of its expression in primary and metastatic RCC. A total of 164 paraffin-embedded tissues of primary RCC and metastatic RCCs from 125 patients were immunostained with CD44 (standard form) antibody. It consisted of 86 primary RCCs (50 with subsequent metastasis [MET+] and 36 with no known metastasis [MET-]) during follow up and 78 metastatic RCCs (39 metastatic RCCs only and 39 with matched RCC primary from RCC MET + category). Immunoreactivity for CD44 was scored semiquantitatively as 0, 1, or 2 (0, < 5%; 1, 5-50%; 2, >= 50%). Expression of CD44 was significantly higher in metastatic RCCs compared to primary RCCs (p=0.036). CD44 immunoreactivity in the primary RCC (MET- and MET+) correlated with progression-free survival (p=0.027). In metastatic RCCs, CD44 immunoreactivity also correlated with survival after detection of first metastasis (p=0.011). In multivariate analysis, stage (p=0.0001) and CD44 immunoreactivity (p=0.03) in primary RCC were independent predictors of progression-free survival. Our study suggests that CD44 status in RCC provides useful prognostic information both in primary and metastatic RCCs and may have applicability in stratifying patients for therapeutic decisions.